ACOG Guideline Backs Early Hormone Therapy for Menopause Symptoms

Key Takeaways

• New menopause standards from the American College of Obstetricians and Gynecologists mostly line up with other societies’suggestions.
• Menopausal hormonal agent treatment got a strong suggestion for vasomotor signs and associated sleep disruptions for females not contraindicated to it.
• The standards highly suggested that menopausal hormonal agent treatment be started before age 60 or within 10 years of the start of natural menopause for proper clients.

Upgraded standards from the American College of Obstetricians and Gynecologists (ACOG)broaden on previous suggestions and line up with a growing cross-specialty agreement on how to handle menopause signs.

For handling vasomotor signs and associated sleep disruptions, ACOG highly suggested systemic hormonal agent treatment with estrogen and a progestogen for ladies with a uterus, or estrogen alone for those who do not need endometrial security. This uses to females without contraindications to hormonal agent treatment and is based upon moderate-quality proof.

Notably, the standards highly suggested that menopausal hormonal agent treatment be started before age 60 or within 10 years of the start of natural menopause for proper clients.

ACOG likewise highly suggested selective serotonin reuptake inhibitors(SSRIs)or serotonin and norepinephrine reuptake inhibitors(SNRIs)for handling vasomotor and depressive signs, and neurokinin receptor agonists for handling vasomotor signs and associated sleep disruptions, in menopausal clients contraindicated to hormonal agent treatment. Both of these suggestions are based upon moderate-to premium proof.

These standards, which change 2014 assistance, were created by ACOG’s Committee on Clinical Practice Guidelines– Gynecology in cooperation with Bruce Pier, MD, Robert Kauffman, MD, MSCP, and Catherine Cansino, MD, MPH, and were released in Obstetrics & & Gynecology; the whole November concern is committed to menopause.

Kauffman kept in mind on a press call that ACOG’s evaluation of the proof discovered that “menopausal hormone therapy is safe and certainly effective for many newly menopausal women.”

JoAnn E. Manson, MD, MPH, DrPH, of Harvard Medical School in Boston and previous president of the Menopause Society, informed MedPage Today that the timing aspect is vital.

Manson, who was not associated with the standards, likewise explained that ACOG’s suggestions are extremely comparable to the American College of Physicians’ current standards, As those of other expert societies.

“I think the good news here is that there’s a growing consensus among professional societies that menopausal symptoms should be treated and that hormone therapy should be the first-line of treatment,” she stated, including that numerous females suffer in silence through menopausal signs.

In between 50% and 92% of females experience hot flashes or night sweats throughout menopause, and 16% to 66% experience menopause-related sleep interruptions, the ACOG committee kept in mind. In addition, more than one in 3 peri- and postmenopausal ladies report depressive signs.

Manson stated that menopausal hormonal agent treatment is underutilized, in part due to the fact that there were black box cautions on a number of items for twenty years based upon preliminary findings from the critical Women’s Health Initiative(WHI )research study; Manson was among the private investigators on that research study.

In the years because, research study has actually assisted to paint a much better image of which clients are suitable prospects and which non-hormonal and nonpharmacological options can support ladies who should not take hormonal agents.

Throughout the presser, Kauffman stated ACOG is “trying to allay this fear that has been out there for the past 20-plus years that menopausal hormone therapy is dangerous, and we’re seeing a sort of a paradigm shift in the tone of the various recommendations.” Previously this year, FDA authorized security caution label modifications to a number of hormonal agent treatment items.

ACOG President Camille Clare, MD, MPH, included that, as menopause awareness has “grown dramatically in recent years, so has the amount of misinformation.”

“That’s why ACOG is expanding our focus on menopause this year, increasing the resources available to both ob/gyns and their patients,” Clare stated on journalism call.

The upgraded assistance concentrates on peri- and postmenopausal individuals appointed woman at birth with vasomotor, sleep, and state of mind signs associated with natural or induced menopause. ACOG kept in mind in a news release that complementary assistance on handling the genitourinary syndrome of menopause will be released in 2027.

“While much of the general principles regarding menopause care, including foundational elements related to the indications and contraindications to these options, have not changed for decades, the availability of newer treatment options to manage menopause-related symptoms is contributing to a renewed interest in menopause education among clinicians,” stated Cansino throughout journalism call.

For this standard, the group performed a literature search on Medline, Ovid, PubMed, and the Cochrane database. They consisted of information from pertinent human-only English-language research studies carried out in nations ranked “very high” on the United Nations Human Development Index. An exception was produced acupuncture research studies from China, which ranked as “high.” Research studies were released from 2013 to March 2024.

Strong suggestions for a treatment indicate that the advantages plainly surpassed damages and problems, while conditional suggestions showed that advantages and dangers differ by client qualities which personalized, shared decision-making ought to be used.

Gabapentin, cognitive behavior modification, mindfulness-based interventions, workout, scientific hypnosis, and acupuncture all got conditional suggestions for some sign relief when other favored treatments are not choices.

ACOG likewise took a look at health inequalities, keeping in mind that females of color, trans individuals, and other marginalized groups might have various experiences with menopause signs and treatments.